const r=(e="")=>e==="prevalence"?t():e==="pathophysiology"?n():e==="pathogenesis"?i():e==="clinical-presentation"?a():e==="management"?o():e==="visual"?s():[{title:"HELLP Syndrome - Comprehensive Clinical Management",clickableItems:[{text:"ðŸ“Š Prevalence & Epidemiology",sectionId:"prevalence"},{text:"âš¡ Pathophysiology",sectionId:"pathophysiology"},{text:"ðŸ§¬ Pathogenesis",sectionId:"pathogenesis"},{text:"ðŸ©º Clinical Presentation",sectionId:"clinical-presentation"},{text:"ðŸ’Š Management & Treatment",sectionId:"management"},{text:"ðŸ—ºï¸ Visual Algorithm and Checklist",sectionId:"visual"}]},{title:"HELLP Syndrome Overview",points:["ðŸ”¤ **Acronym**: Hemolysis, Elevated Liver enzymes, Low Platelets","ðŸ“Š **Incidence**: 0.2-0.6% of all pregnancies, 10-20% of preeclampsia with severe features","âš¡ **Onset**: 70% antepartum, 30% postpartum (up to 7 days)","ðŸŽ¯ **Peak Incidence**: 27-37 weeks gestation","âš ï¸ **Mortality**: Maternal mortality 1-25%, perinatal mortality 10-60%","ðŸš¨ **Emergency**: Life-threatening obstetric emergency requiring immediate management"]}],t=()=>[{title:"Prevalence and Epidemiology of HELLP Syndrome",subsections:[{title:"Global Incidence",points:["ðŸ“Š **Overall Incidence**: 0.2-0.6% of all pregnancies","âš¡ **Preeclampsia Association**: 10-20% of preeclampsia with severe features cases","ðŸŒ **Geographic Variation**: Higher in Caucasian populations","ðŸ“ˆ **Trend**: Increasing recognition and diagnosis","ðŸ¥ **Hospital Series**: 0.5-0.9% in tertiary centers"]}]}],n=()=>[{title:"Pathophysiology of HELLP Syndrome",subsections:[{title:"Microangiopathic Process",points:["ðŸ©¸ **Endothelial Damage**: Primary endothelial cell injury","âš¡ **Microthrombi Formation**: Platelet aggregation in microvasculature","ðŸ”„ **Fibrin Deposition**: Intravascular coagulation","ðŸ’« **Red Cell Fragmentation**: Mechanical hemolysis through fibrin strands"]}]}],i=()=>[{title:"Pathogenesis of HELLP Syndrome",subsections:[{title:"Placental Origin Theory",points:["ðŸŒ± **Placental Ischemia**: Inadequate trophoblast invasion","ðŸ©¸ **Spiral Artery Remodeling**: Failed physiological transformation","âš¡ **Oxidative Stress**: Increased reactive oxygen species","ðŸ”„ **Inflammatory Response**: Maternal systemic inflammation"]}]}],a=()=>[{title:"Clinical Presentation of HELLP Syndrome",subsections:[{title:"Early Symptoms",points:["ðŸ˜Ÿ **Malaise**: General feeling of unwellness (90%)","ðŸ’” **Epigastric Pain**: Right upper quadrant pain (65-90%)","ðŸ¤¢ **Nausea and Vomiting**: Often severe, persistent (84%)","ðŸ¤• **Headache**: Often severe, frontal (33%)"]}]}],o=()=>[{title:"Management of HELLP Syndrome",subsections:[{title:"Emergency Management",points:["ðŸš¨ **ABCs**: Airway, breathing, circulation assessment","ðŸ’‰ **IV Access**: Large bore cannula for fluid/blood products","ðŸ“Š **Vital Signs**: Continuous monitoring","ðŸ¤± **Primary Treatment**: Delivery is curative"]}]}],s=()=>[{title:"HELLP Syndrome â€“ Visual Algorithm (Tabbed)",points:["**TAB_START: Flowchart**","```mermaid","flowchart TD","  A[Recognize HELLP (labs/platelets)] --> B[Start MgSO4]","  B --> C[Control BP: labetalol/hydralazine/nifedipine]","  C --> D[Delivery timing per GA & maternal status]","  D --> E[Blood products: platelets/FFP thresholds]","  E --> F[ICU/HDU care and postpartum monitoring]","```","**TAB_END**","**TAB_START: Checklist**","Time-critical steps; platelet transfusion thresholds; anesthesia considerations; debrief and follow-up","**TAB_END**"]}];export{r as getComprehensiveHELLPContent};
